SciClone China CEO Mark Lotter On The Changing Commercial Landscape: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Considered one of the top commercial minds in China, the former AstraZeneca exec and founder of NovaMed discusses how to build a sustainable commercial model in a rapidly changing China, touching on everything from retaining talent to surviving China’s latest round of price cuts.
You may also be interested in...
HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18